Recombinant modified vaccinia virus Ankara-based malaria vaccines

Expert Review of Vaccines

Volumn 15, Issue 1, 2016, Pages 91-103

  Sebastian, Sarah ^a   Gilbert, Sarah C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

clinical trials; heterologous prime boost; malaria; modified vaccinia virus Ankara (MVA); plasmodium; vaccine

Indexed keywords

BLOOD STAGE VACCINE; MALARIA VACCINE; PRE ERYTHROCYTIC VACCINE; RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA BASED MALARIA VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; DRUG CARRIER;

ANTIBODY TITER; ANTIGEN SPECIFICITY; CD4+ T LYMPHOCYTE; DISEASE TRANSMISSION; GOOD MANUFACTURING PRACTICE; HOMOLOGOUS RECOMBINATION; HUMAN; IMMUNE RESPONSE; LIFE CYCLE STAGE; MALARIA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TARGET CELL; VACCINIA VIRUS; VIRUS PURIFICATION; CLINICAL TRIAL (TOPIC); GENE VECTOR; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; ISOLATION AND PURIFICATION;

CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; GENETIC VECTORS; HUMANS; MALARIA VACCINES; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 84951568308     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2016.1106319     Document Type: Review

References (107)

1. Papers of special note have been highlighted as: ∗ of interest
2. ∗ of considerable interest
3. World Malaria Report. World Health Organization. 2014 [. cited 2015 Aug 25 ]. Available from: http://wwwwhoint/malaria/publications/world-malaria-report-2014/en/.
4. Miller LH, Ackerman HC, Su XZ., et al. Malaria biology and disease pathogenesis: insights for new treatments. Nat Med. 2013; 19 (2): 156-167.
5. Kirkman LA, Deitsch KW. Antigenic variation and the generation of diversity in malaria parasites. Curr Opin Microbiol. 2012; 15 (4): 456-462.
6. Bolad A, Berzins K. Antigenic diversity of P lasmodium falciparum and antibody-mediated parasite neutralization. Scand J Immunol. 2000; 52 (3): 233-239.
7. Olotu A, Lusingu J, Leach A., et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis. 2011; 11 (2): 102-109.
8. Douglas AD, Baldeviano GC, Lucas CM., et al. A PfRH5-based vaccine is efficacious against Heterologous strain blood-stage P lasmodium falciparum infection in A otus monkeys. Cell Host Microbe. 2015; 17 (1): 130-139.
9. Biswas S, Spencer AJ, Forbes EK., et al. Recombinant viral-vectored vaccines expressing P lasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection. J Immunol. 2012; 188 (10): 5041-5053.
10. Douglas AD, de Cassan SC, Dicks MD., et al. Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against P lasmodium falciparum MSP1. Vaccine. 2010; 28 (44): 7167-7178.
11. Romero P, Maryanski JL, Corradin G., et al. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature. 1989; 341 (6240): 323-326.
12. Todryk SM, Bejon P, Mwangi T., et al. Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans. PLoS One. 2008; 3 (4): e2027.
13. Mayr A, Hochstein-Mintzel V, Stickl H. Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA. Infection. 1975; 3: 6-14.
14. Mayr A, Stickl H, Müller HK., et al. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (authors transl). Zentralbl Bakteriol B. 1978; 167 (5-6): 375-390. German.
15. Overton ET, Stapleton J, Frank I., et al. Safety and immunogenicity of modified vaccinia Ankara-Bavarian Nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: an open-label, controlled clinical phase II trial. Open Forum Infect Dis. 2015; 2 (2): ofv040.
16. Bronte V, Carroll MW, Goletz TJ., et al. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci U S A. 1997; 94 (7): 3183-3188.
17. Baur K, Brinkmann K, Schweneker M., et al. Immediate-early expression of a recombinant antigen by modified vaccinia virus Ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses. J Virol. 2010; 84 (17): 8743-8752.
18. Jordan I, Northoff S, Thiele M., et al. A chemically defined production process for highly attenuated poxviruses. Biologicals. 2011; 39 (1): 50-58.
19. Jordan I, Vos A, Beilfuss S., et al. An avian cell line designed for production of highly attenuated viruses. Vaccine. 2009; 27 (5): 748-756.
20. Kraus B, von Fircks S, Feigl S., et al. Avian cell line: technology for large scale vaccine production. BMC Proc. 2011; 5 (Suppl 8): P52.
21. Brown SW, Mehtali M. The avian EB66(R) cell line, application to vaccines, and therapeutic protein production. PDA J Pharm Sci Technol. 2010; 64 (5): 419-425.
22. A Phase I study to assess Ebola vaccines cAd3-EBO Z and MVA-EBO Z. Available from: https://clinicaltrialsgov/ct2/show/NCT02451891.
23. Wolff MW, Siewert C, Hansen SP., et al. Purification of cell culture-derived modified vaccinia Ankara virus by pseudo-affinity membrane adsorbers and hydrophobic interaction chromatography. Biotechnol Bioeng. 2010; 107 (2): 312-320.
24. Wolff MW, Siewert C, Lehmann S., et al. Capturing of cell culture-derived modified vaccinia Ankara virus by ion exchange and pseudo-affinity membrane adsorbers. Biotechnol Bioeng. 2010; 105 (4): 761-769.
25. Alcock R, Cottingham MG, Rollier CS., et al. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci Transl Med. 2010; 2 (19): 19ra12.
26. Schneider J, Gilbert SC, Blanchard TJ., et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med. 1998; 4 (4): 397-402.
27. Gilbert SC, Schneider J, Plebanski M., et al. Ty virus-like particles, DNA vaccines and modified vaccinia virus Ankara; comparisons and combinations. Biol Chem. 1999; 380 (3): 299-303.
28. Gilbert SC, Schneider J, Hannan CM., et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine. 2002; 20 (7-8): 1039-1045.
29. Gonzalez-Aseguinolaza G, Nakaya Y, Molano A., et al. Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of P lasmodium yoelii. J Virol. 2003; 77 (21): 11859-11866.
30. Li S, Rodrigues M, Rodriguez D., et al. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci U S A. 1993; 90 (11): 5214-5218.
31. Reyes-Sandoval A, Berthoud T, Alder N., et al. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun. 2010; 78 (1): 145-153.
32. Reyes-Sandoval A, Wyllie DH, Bauza K., et al. CD8+ T effector memory cells protect against liver-stage malaria. J Immunol. 2011; 187 (3): 1347-1357.
33. Capone S, Reyes-Sandoval A, Naddeo M., et al. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine. 2010; 29 (2): 256-265.
34. Rodriguez D, Gonzalez-Aseguinolaza G, Rodriguez JR., et al. Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of P lasmodium. PLoS One. 2012; 7 (4): e34445.
35. Vijayan A, Gomez CE, Espinosa DA., et al. Adjuvant-like effect of vaccinia virus 14K protein: a case study with malaria vaccine based on the circumsporozoite protein. J Immunol. 2012; 188 (12): 6407-6417.
36. Spencer AJ, Hill F, Honeycutt JD., et al. Fusion of the M ycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates. PLoS One. 2012; 7 (3): e33555.
37. Bauza K, Malinauskas T, Pfander C., et al. Efficacy of a P lasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic P lasmodium berghei parasites. Infect Immun. 2014; 82 (3): 1277-1286.
38. Longley RJ, Salman AM, Cottingham MG., et al. Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates. Sci Rep. 2015; 5: 11820.
39. Draper SJ, Goodman AL, Biswas S., et al. Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria. Cell Host Microbe. 2009; 5 (1): 95-105.
40. Xu H, Hodder AN, Yan H., et al. CD4+ T cells acting independently of antibody contribute to protective immunity to P lasmodium chabaudi infection after apical membrane antigen 1 immunization. J Immunol. 2000; 165 (1): 389-396.
41. Goodman AL, Epp C, Moss D., et al. New candidate vaccines against blood-stage P lasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1. Infect Immun. 2010; 78 (11): 4601-4612.
42. Draper SJ, Biswas S, Spencer AJ., et al. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J Immunol. 2010; 185 (12): 7583-7595.
43. Forbes EK, Biswas S, Collins KA., et al. Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference. J Immunol. 2011; 187 (7): 3738-3750.
44. de Cassan SC, Shakri AR, Llewellyn D., et al. Preclinical assessment of viral vectored and protein vaccines targeting the Duffy-binding protein Region II of Plasmodium v ivax. Front Immunol. 2015; 6: 348.
45. Goodman AL, Blagborough AM, Biswas S., et al. A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity. PLoS One. 2011; 6 (12): e29428.
46. Kapulu MC, Da DF, Miura K., et al. Comparative assessment of transmission-blocking vaccine candidates against P lasmodium falciparum. Sci Rep. 2015; 5: 11193.
47. Williams AR, Zakutansky SE, Miura K., et al. Immunisation against a serine protease inhibitor reduces intensity of P lasmodium berghei infection in mosquitoes. Int J Parasitol. 2013; 43 (11): 869-874.
48. Dunachie SJ, Walther M, Epstein JE., et al. A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against P lasmodium falciparum sporozoite challenge. Infect Immun. 2006; 74 (10): 5933-5942.
49. Walther M, Thompson FM, Dunachie S., et al. Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length P lasmodium falciparum circumsporozoite protein. Infect Immun. 2006; 74 (5): 2706-2716.
50. Imoukhuede EB, Berthoud T, Milligan P., et al. Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men. Vaccine. 2006; 24 (42-43): 6526-6533.
51. Dunachie SJ, Walther M, Vuola JM., et al. A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine. 2006; 24 (15): 2850-2859.
52. Porter DW, Thompson FM, Berthoud TK., et al. A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine. 2011; 29 (43): 7514-7522.
53. Ockenhouse CF, Sun PF, Lanar DE., et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for P lasmodium falciparum malaria. J Infect Dis. 1998; 177 (6): 1664-1673.
54. Hodgson SH, Ewer KJ, Bliss CM., et al. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J Infect Dis. 2015; 211 (7): 1076-1086.
55. O'Hara GA, Duncan CJ, Ewer KJ., et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis. 2012; 205 (5): 772-781.
56. Ewer KJ, O'Hara GA, Duncan CJ., et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun. 2013; 4: 2836.
57. Ogwang C, Afolabi M, Kimani D., et al. Safety and immunogenicity of heterologous prime-boost immunisation with P lasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS One. 2013; 8 (3): e57726.
58. Ogwang C, Kimani D, Edwards NJ., et al. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against P lasmodium falciparum infection in Kenyan adults. Sci Transl Med. 2015; 7 (286): 286re5.
59. Sheehy SH, Duncan CJ, Elias SC., et al. Phase Ia clinical evaluation of the safety and immunogenicity of the P lasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One. 2012; 7 (2): e31208.
60. Sheehy SH, Duncan CJ, Elias SC., et al. Phase Ia clinical evaluation of the P lasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther. 2011; 19 (12): 2269-2276.
61. Hodgson SH, Choudhary P, Elias SC., et al. Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial. Mol Ther. 2014; 22 (12): 2142-2154.
62. Sheehy SH, Duncan CJ, Elias SC., et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther. 2012; 20 (12): 2355-2368.
63. Menard R, Sultan AA, Cortes C., et al. Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes. Nature. 1997; 385 (6614): 336-340.
64. Coppi A, Natarajan R, Pradel G., et al. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. J Exp Med. 2011; 208 (2): 341-356.
65. Plassmeyer ML, Reiter K, Shimp RL Jr., et al. Structure of the P lasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate. J Biol Chem. 2009; 284 (39): 26951-26963.
66. Ghosh AK, Devenport M, Jethwaney D., et al. Malaria parasite invasion of the mosquito salivary gland requires interaction between the P lasmodium TRAP and the A nopheles saglin proteins. PLoS Pathog. 2009; 5 (1): e1000265.
67. Sultan AA, Thathy V, Frevert U., et al. TRAP is necessary for gliding motility and infectivity of plasmodium sporozoites. Cell. 1997; 90 (3): 511-522.
68. Akhouri RR, Sharma A, Malhotra P., et al. Role of P lasmodium falciparum thrombospondin-related anonymous protein in host-cell interactions. Malar J. 2008; 7: 63.
69. Robson KJ, Frevert U, Reckmann I., et al. Thrombospondin-related adhesive protein (TRAP) of P lasmodium falciparum: expression during sporozoite ontogeny and binding to human hepatocytes. Embo J. 1995; 14 (16): 3883-3894.
70. Guerin-Marchand C, Druilhe P, Galey B., et al. A liver-stage-specific antigen of P lasmodium falciparum characterized by gene cloning. Nature. 1987; 329 (6135): 164-167.
71. Fidock DA, Gras-Masse H, Lepers JP., et al. Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants. J Immunol. 1994; 153 (1): 190-204.
72. Kurtis JD, Hollingdale MR, Luty AJ., et al. Pre-erythrocytic immunity to P lasmodium falciparum: the case for an LSA-1 vaccine. Trends Parasitol. 2001; 17 (5): 219-223.
73. Hillier CJ, Ware LA, Barbosa A., et al. Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for P lasmodium falciparum. Infect Immun. 2005; 73 (4): 2109-2115.
74. Mikolajczak SA, Sacci JB Jr., De La Vega P., et al. Disruption of the P lasmodium falciparum liver-stage antigen-1 locus causes a differentiation defect in late liver-stage parasites. Cell Microbiol. 2011; 13 (8): 1250-1260.
75. Siau A, Silvie O, Franetich JF., et al. Temperature shift and host cell contact up-regulate sporozoite expression of P lasmodium falciparum genes involved in hepatocyte infection. PLoS Pathog. 2008; 4 (8): e1000121.
76. Holder AA, Blackman MJ, Burghaus PA., et al. A malaria merozoite surface protein (MSP1)-structure, processing and function. Mem Inst Oswaldo Cruz. 1992; 87 (Suppl 3): 37-42.
77. Blackman MJ, Heidrich HG, Donachie S., et al. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med. 1990; 172 (1): 379-382.
78. Sacci JB Jr., Ribeiro JM, Huang F., et al. Transcriptional analysis of in vivo P lasmodium yoelii liver stage gene expression. Mol Biochem Parasitol. 2005; 142 (2): 177-183.
79. Silvie O, Franetich JF, Charrin S., et al. A role for apical membrane antigen 1 during invasion of hepatocytes by P lasmodium falciparum sporozoites. J Biol Chem. 2004; 279 (10): 9490-9496.
80. Pizarro JC, Vulliez-Le Normand B, Chesne-Seck ML., et al. Crystal structure of the malaria vaccine candidate apical membrane antigen 1. Science. 2005; 308 (5720): 408-411.
81. Remarque EJ, Faber BW, Kocken CH., et al. Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol. 2008; 24 (2): 74-84.
82. Mitchell GH, Thomas AW, Margos G., et al. Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cells. Infect Immun. 2004; 72 (1): 154-158.
83. Bargieri DY, Andenmatten N, Lagal V., et al. Apical membrane antigen 1 mediates apicomplexan parasite attachment but is dispensable for host cell invasion. Nat Commun. 2013; 4: 2552.
84. Wright KE, Hjerrild KA, Bartlett J., et al. Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies. Nature. 2014; 515 (7527): 427-430.
85. Rodriguez M, Lustigman S, Montero E., et al. PfRH5: a novel reticulocyte-binding family homolog of P lasmodium falciparum that binds to the erythrocyte, and an investigation of its receptor. PLoS One. 2008; 3 (10): e3300.
86. Baum J, Chen L, Healer J., et al. Reticulocyte-binding protein homologue 5-an essential adhesin involved in invasion of human erythrocytes by P lasmodium falciparum. Int J Parasitol. 2009; 39 (3): 371-380.
87. van Dijk MR, Janse CJ, Thompson J., et al. A central role for P48/45 in malaria parasite male gamete fertility. Cell. 2001; 104 (1): 153-164.
88. Gerloff DL, Creasey A, Maslau S., et al. Structural models for the protein family characterized by gamete surface protein Pfs230 of P lasmodium falciparum. Proc Natl Acad Sci U S A. 2005; 102 (38): 13598-13603.
89. Eksi S, Czesny B, van Gemert GJ., et al. Malaria transmission-blocking antigen, Pfs230, mediates human red blood cell binding to exflagellating male parasites and oocyst production. Mol Microbiol. 2006; 61 (4): 991-998.
90. Tomas AM, Margos G, Dimopoulos G., et al. P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions. Embo J. 2001; 20 (15): 3975-3983.
91. Baton LA, Ranford-Cartwright LC. Do malaria ookinete surface proteins P25 and P28 mediate parasite entry into mosquito midgut epithelial cells? Malar J. 2005; 4: 15.
92. A safety and efficacy study of concomitant administration of ChAd63/MVA ME-TRAP + RTS,S. Available from: https://clinicaltrialsgov/ct2/show/NCT02252640.
93. A Phase I study to assess the safety and immunogenicity of ChAd63 ME-TRAP-MVA ME-TRAP heterologous prime-boost vaccination co-administered with EPI vaccines in Gambian infants. Available from: https://clinicaltrialsgov/ct2/show/NCT02083887.
94. A Phase Ia clinical trial to assess the safety and immunogenicity of new Plasmodium f alciparum malaria vaccine candidates ChAd63 RH5 alone and with MVA RH5. Available from: https://clinicaltrialsgov/ct2/show/NCT02181088.
95. A safety and efficacy study of ChAd63/MVA METRAP + RTS,S. Available from: https://clinicaltrialsgov/ct2/show/NCT01883609.
96. A Phase I/IIa sporozoite challenge study to assess the efficacy of candidate combination malaria vaccine approaches using the ChAd63 and MVA vectors encoding the antigens ME-TRAP, CS and AMA1. Available from: https://clinicaltrialsgov/ct2/show/NCT01739036.
97. Phase Ia study of ChAd63/MVA PvDBP. Available from: https://clinicaltrialsgov/ct2/show/NCT01816113.
98. A Phase 1/2b study of an investigational malaria vaccination strategy in 5-17 month old infants and children in Burkina Faso. Available from: https://clinicaltrialsgov/ct2/show/NCT01635647.
99. Adjuvanting viral vectored malaria vaccines with Matrix M. Available from: https://clinicaltrialsgov/ct2/show/NCT01669512.
100. Efficacy of candidate malaria vaccines in Senegalese adults. Available from: https://clinicaltrialsgov/ct2/show/NCT01658696.
101. Safety and immunogenicity of novel vaccination schedules with malaria vaccines AdCh63 ME-TRAP and MVA ME-TRAP. Available from: https://clinicaltrialsgov/ct2/show/NCT01364883.
102. AdCh63 ME-TRAP and MVA ME-TRAP malaria vaccines evaluation in healthy children in a malaria endemic area. Available from: https://clinicaltrialsgov/ct2/show/NCT01450293.
103. Kimani D, Jagne YJ, Cox M., et al. Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. Mol Ther. 2014; 22 (11): 1992-2003.
104. Biswas S, Choudhary P, Elias SC., et al. Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure. PLoS One. 2014; 9 (9): e107903.
105. Elias SC, Collins KA, Halstead FD., et al. Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection. J Immunol. 2013; 190 (3): 1135-1147.
106. De Barra E, Hodgson SH, Ewer KJ., et al. A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS. PLoS One. 2014; 9 (12): e115161.
107. Thompson FM, Porter DW, Okitsu SL., et al. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS One. 2008; 3 (1): e1493.